이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Spectral Medical 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Chris Seto

최고 경영자

CA$754.3k

총 보상

CEO 급여 비율	61.2%
CEO 임기	3.2yrs
CEO 소유권	0.4%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	3yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Chris Seto 의 보수는 Spectral Medical 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-CA$19m
Dec 31 2023	CA$754k	CA$462k	-CA$16m
Sep 30 2023	n/a	n/a	-CA$10m
Jun 30 2023	n/a	n/a	-CA$9m
Mar 31 2023	n/a	n/a	-CA$7m
Dec 31 2022	CA$901k	CA$457k	-CA$8m
Sep 30 2022	n/a	n/a	-CA$7m
Jun 30 2022	n/a	n/a	-CA$7m
Mar 31 2022	n/a	n/a	-CA$7m
Dec 31 2021	CA$883k	CA$419k	-CA$7m
Sep 30 2021	n/a	n/a	-CA$8m
Jun 30 2021	n/a	n/a	-CA$8m
Mar 31 2021	n/a	n/a	-CA$7m
Dec 31 2020	CA$590k	CA$338k	-CA$9m
Sep 30 2020	n/a	n/a	-CA$8m
Jun 30 2020	n/a	n/a	-CA$8m
Mar 31 2020	n/a	n/a	-CA$7m
Dec 31 2019	CA$391k	CA$139k	-CA$5m

보상 대 시장: Chris 의 총 보상 ($USD 550.21K )은 Canadian 시장( $USD 175.07K ).

보상과 수익: Chris 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Chris Seto

3.2yrs

테뉴어

CA$754,295

보상

Mr. Christopher Seto, also known as Chris, serves as Chief Financial Officer, Chief Executive Officer and Director for Spectral Medical Inc. since December 01, 2023, November 12, 2021 and April 01, 2021 re...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Christopher Seto	CEO, CFO & Director	2.6yrs	CA$754.30k	0.42% CA$ 582.4k
Paul Walker	Independent Chairman of the Board	23.2yrs	CA$103.13k	0.74% CA$ 1.0m
Janelle D'Alvise	Independent Director	3yrs	CA$122.02k	데이터 없음
David Feigal	Independent Director	less than a year	CA$89.27k	데이터 없음
William Stevens	Independent Director	9.8yrs	CA$114.25k	0.31% CA$ 435.9k
Cristiano Franzi	Independent Director	no data	데이터 없음	데이터 없음
Jun Hayakawa	Independent Director	6.1yrs	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

71yo

평균 연령

경험이 풍부한 이사회: EDT 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Spectral Medical 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Independent Chairman of the Board exercised options to buy CA$102k worth of stock.

Less than half of directors are independent

Spectral Medical Inc. Announces Board Changes

Spectral Medical Inc., Annual General Meeting, Jun 07, 2024

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Executive Changes

Recent updates

Independent Chairman of the Board exercised options to buy CA$102k worth of stock.

Spectral Medical Inc. announced that it has received CAD 8.499564 million in funding

First quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.006 loss in 1Q 2023)

Spectral Medical Inc. announced that it expects to receive CAD 8.499564 million in funding

Spectral Medical Inc. Provides Tigris Trial Update

Spectral Medical Provides Tigris Trial Update

Less than half of directors are independent

Price target increased by 13% to CA$1.80

Spectral Medical Inc. Announces Board Changes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Spectral Medical Inc., Annual General Meeting, Jun 07, 2024

New minor risk - Market cap size

Spectral Medical Inc. Provides Update on the Company's Tigris Trial

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Spectral Medical Inc. Provides Early February Tigris Trial Update

Spectral Medical Provides January Tigris Trial Update

Spectral Medical Inc. l Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial

Spectral Medical Inc. Provides November Tigris Trial Update

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Publication of Tigris Trial Methods Paper

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Provides Tigris Trial Update

New minor risk - Shareholder dilution

Spectral Medical Inc. announced that it has received CAD 6.217075 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 5 million in funding from Paradigm Capital Inc.

Second quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.011 loss in 2Q 2022)

Spectral Medical Inc. Announces Tigris Clinical Trial Update

Spectral Medical Inc. Appoints David W. Feigal to Its Board of Directors

Spectral Medical Inc. Provides Update on Continued Favorable Tigris Clinical Trial Enrollment

Spectral Medical Inc. Provides Update on Favorable Tigris Clinical Trial Enrollment

Consensus revenue estimates increase by 186%

Consensus revenue estimates decrease by 61%, EPS upgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Inc. Announces Resignation of Jim Funk as Director

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Spectral Medical Inc. Provides Update on Tigris Clinical Trial

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CA$2.10

Forecast to breakeven in 2024

Spectral Medical Inc. announced that it has received CAD 6.8364 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Spectral Medical Provides Update on Tigris Clinical Trial

US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ for the Treatment of Endotoxemic Septic Shock

Spectral Medical Inc. Elects James Funk as Director

Spectral Medical Inc. Appoints Sam Amory as Dialco, President

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to CA$2.10

Forecast breakeven date pushed back to 2024

Consensus revenue estimates fall by 44%

Spectral Medical Inc., Annual General Meeting, Jun 09, 2022

Spectral Medical Inc. Through Its Wholly-Owned Subsidiary Dialco Medical Inc. Provides Clinical Trial Update on Tigris, A Follow on Study Designed to Build on Knowledge Gained from the Earlier Euphrates Trial

We're Keeping An Eye On Spectral Medical's (TSE:EDT) Cash Burn Rate

Forecast to breakeven in 2023

Third quarter 2021 earnings released: CA$0.008 loss per share (vs CA$0.007 loss in 3Q 2020)

Price target decreased to CA$2.85

Independent Chairman of the Board recently bought CA$180k worth of stock

Independent Director Kevin Giese has left the company

Forecast breakeven moved forward to 2022

First quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.015 loss in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: CA$0.039 loss per share (vs CA$0.022 loss in FY 2019)

Spectral Medical Inc.'s (TSE:EDT) Path To Profitability

Spectral Medical Inc., Annual General Meeting, Jun 03, 2021